Matthew Fenton

Matthew Fenton

Auto-generated profile, based on publicly available information

Matthew Fenton

Great Ormond Street Hospital for Children Foundation Trust London UK

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2008 in Heart
Verified
Journal Article
Closed access
PDF file
Juan Pablo KaskiJuan Pablo Kaski
Juan Pablo Kaski
PSPetros Syrris
Petros Syrris
MBM Burch
M Burch
MTM-T Tomé-Esteban
M-T Tomé-Esteban
MFM Fenton
M Fenton
Perry ElliottPerry Elliott
Perry Elliott
Background: Restrictive cardiomyopathy (RCM) is rare in childhood, but has a grave prognosis. The cause of disease in most cases is unknown. Objective: To determine the prevalence of sarcomere protein gene mutations in children with idiopathic RCM. Methods: Twelve patients (9 female, mean age 5.1 years) with idiopathic RCM referred between 1991 and August 2006 underwent detailed clinical and genetic evaluation. Nine had received cardiac transplants at the time of the study. The entire coding sequences of the genes encoding eight cardiac sarcomere proteins and desmin were screened for mutations. Familial evaluation was performed on first-degree relatives. Results: Four patients (33%) had a family history of cardiomyopathy: RCM (n = 2); dilated cardiomyopathy (n = 1) and left ventricular non-compaction (n = 1). Sarcomere protein gene mutations were identified in four patients (33%): 2 in the cardiac troponin I gene (TNNI3) and 1 each in the troponin T (TNNT2) and α-cardiac actin (ACTC) genes. Two were de novo mutations and 3 were new mutations. All mutations occurred in functionally important and conserved regions of the genes. Conclusions: Sarcomere protein gene mutations are an important cause of idiopathic RCM in childhood. We describe the first mutation in ACTC in familial RCM. The identification of RCM in a child should prompt consideration of sarcomere protein disease as a possible cause and warrants clinical evaluation of the family.

1 January 2008 in Circulation
Verified
Journal Article
Closed access
PDF file
RARachel E. Andrews
Rachel E. Andrews
MFMatthew J. Fenton
Matthew J. Fenton
DRDeborah A. Ridout
Deborah A. Ridout
MBMichael Burch
Michael Burch
Background— We undertook the first prospective, national, multicenter study to describe the incidence and outcome of heart muscle disease–induced heart failure in children. Methods and Results— Data were collected on patients admitted to a hospital through 2003 with a first episode of heart failure in the absence of congenital heart disease. All 17 pediatric cardiac centers in the United Kingdom and Ireland participated. Follow-up data were obtained to a minimum of 1 year. The incidence was 0.87/100 000 population <16 years (n=104; 53 girls; 95% confidence interval 0.71 to 1.05 per 100 000). Median age at presentation was 1 year, with 82% in New York Heart Association class III to IV. Causes of heart failure included dilated cardiomyopathy (50 idiopathic, 8 familial), probable myocarditis (23), occult arrhythmia (7), anthracycline toxicity (5), metabolic disease (4), left ventricular noncompaction (3), and other (4). Overall 1-year survival was 82%, and event (death or transplantation)-free survival was 66%. Regression analysis showed older age and reduced systolic function on admission echocardiogram increased the event risk. Only 8% of event-free survivors (n=69) remained in New York Heart Association class III to IV, but 35 required readmission during the study period, and all but 8 remained on medication. Conclusions— This first national prospective study of new-onset heart failure in children has shown an incidence of 0.87/100 000. Multivariable analysis of survival data indicates a better outcome for younger children and for those with better systolic function at presentation, but overall, one third of children die or require transplantation within 1 year of presentation.

1 November 2013 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
JCJane Cassidy
Jane Cassidy
TDTroy Dominguez
Troy Dominguez
SHSimon Haynes
Simon Haynes
MBMichael Burch
Michael Burch
RKRichard Kirk
Richard Kirk
AKAnn Karimova
Ann Karimova

3 April 2007 in Circulation
Verified
Journal Article
Closed access
PDF file
THTarique Hussain
Tarique Hussain
MBMichael Burch
Michael Burch
MFMatthew J. Fenton
Matthew J. Fenton
PWPauline M. Whitmore
Pauline M. Whitmore
PRPhilip Rees
Philip Rees
PAPaul Aurora
Paul Aurora
Background— Cytomegalovirus (CMV) infection has been implicated as a cause of posttransplantation coronary artery disease in adults. The purpose of this retrospective observational study was to evaluate the effect of CMV on outcome after heart transplantation in children. Methods and Results— Risk factors tested were recipient age, sex, and pretransplantation CMV serology; use of anti-CMV prophylaxis; posttransplantation evidence of CMV infection; and donor CMV serology. Transplantations were stratified traditionally according to CMV risk as low risk (recipient negative/donor negative), intermediate risk (recipient positive), and high risk (recipient negative/donor positive). Primary outcome measures were (1) development of coronary artery vasculopathy, (2) mortality (or graft loss) that occurred outside the early postoperative period, and (3) death (or graft loss) due to vasculopathy. Analysis was by proportional hazards modeling. A total of 165 children underwent heart transplantation, with a mean age at transplantation of 7.8 (SD 5.6) years. Thirty-two children had laboratory evidence of CMV infection after transplantation, but only 6 developed CMV disease or syndrome. Traditional CMV risk stratification correlated well with CMV infection but did not predict mortality, coronary artery disease, or coronary death. In contrast, positive recipient CMV was the only independent predictor of all 3 outcome measures: coronary artery disease (hazard ratio=3.6), all-cause mortality (partial hazard ratio=4.1), and coronary death (hazard ratio=4.6). Conclusions— In children, pretransplantation recipient CMV status is a more powerful predictor for the development of clinically significant vasculopathy and subsequent death than traditional risk stratification. This phenomenon warrants further investigation.

26 October 2015 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
ABA. Broomfield
A. Broomfield
JFJ. Fletcher
J. Fletcher
JDJ. Davison
J. Davison
NFN. Finnegan
N. Finnegan
MFM. Fenton
M. Fenton
AVA. Vellodi
A. Vellodi

1 July 2015 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
ABA. Brunklaus
A. Brunklaus
EPE. Parish
E. Parish
FMF. Muntoni
F. Muntoni
SSS. Scuplak
S. Scuplak
STS.K. Tucker
S.K. Tucker
AMA.Y. Manzur
A.Y. Manzur